Molecular Insights and Emerging Strategies for Treatment of Metastatic Uveal Melanoma

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2020 Sep 30

PMID 32992823

Citations 22

Authors

Fabiana Mallone

Marta Sacchetti

Alessandro Lambiase

Antonietta Moramarco

Affiliations

Soon will be listed here.

Abstract

Uveal melanoma (UM) is the most common intraocular cancer. In recent decades, major advances have been achieved in the diagnosis and prognosis of UM allowing for tailored treatments. However, nearly 50% of patients still develop metastatic disease with survival rates of less than 1 year. There is currently no standard of adjuvant and metastatic treatment in UM, and available therapies are ineffective resulting from cutaneous melanoma protocols. Advances and novel treatment options including liver-directed therapies, immunotherapy, and targeted-therapy have been investigated in UM-dedicated clinical trials on single compounds or combinational therapies, with promising results. Therapies aimed at prolonging or targeting metastatic tumor dormancy provided encouraging results in other cancers, and need to be explored in UM. In this review, the latest progress in the diagnosis, prognosis, and treatment of UM in adjuvant and metastatic settings are discussed. In addition, novel insights into tumor genetics, biology and immunology, and the mechanisms underlying metastatic dormancy are discussed. As evident from the numerous studies discussed in this review, the increasing knowledge of this disease and the promising results from testing of novel individualized therapies could offer future perspectives for translating in clinical use.

Citing Articles

Recent Advances in Molecular and Genetic Research on Uveal Melanoma.

Fuentes-Rodriguez A, Mitchell A, Guerin S, Landreville S Cells. 2024; 13(12.

PMID: 38920653 PMC: 11201764. DOI: 10.3390/cells13121023.

Ergolide mediates anti-cancer effects on metastatic uveal melanoma cells and modulates their cellular and extracellular vesicle proteomes.

Sundaramurthi H, Tonelotto V, Wynne K, OConnell F, OReilly E, Costa-Garcia M Open Res Eur. 2023; 3:88.

PMID: 37981907 PMC: 10654492. DOI: 10.12688/openreseurope.15973.2.

Cross talk between tumor stemness and microenvironment for prognosis and immunotherapy of uveal melanoma.

Wan Q, Ren X, Tang J, Ma K, Deng Y J Cancer Res Clin Oncol. 2023; 149(13):11951-11968.

PMID: 37420017 DOI: 10.1007/s00432-023-05061-x.

Deep learning classification of uveal melanoma based on histopathological images and identification of a novel indicator for prognosis of patients.

Wan Q, Ren X, Wei R, Yue S, Wang L, Yin H Biol Proced Online. 2023; 25(1):15.

PMID: 37268878 PMC: 10239131. DOI: 10.1186/s12575-023-00207-0.

Chick Chorioallantoic Membrane as a Patient-Derived Xenograft Model for Uveal Melanoma: Imaging Modalities for Growth and Vascular Evaluation.

Tsimpaki T, Bechrakis N, Seitz B, Kraemer M, Liu H, Dalbah S Cancers (Basel). 2023; 15(5).

PMID: 36900228 PMC: 10000919. DOI: 10.3390/cancers15051436.

References

Shields C, Kaliki S, Livesey M, Walker B, Garoon R, Bucci M . Association of ocular and oculodermal melanocytosis with the rate of uveal melanoma metastasis: analysis of 7872 consecutive eyes. JAMA Ophthalmol. 2013; 131(8):993-1003. DOI: 10.1001/jamaophthalmol.2013.129. View

Ambrosini G, Musi E, Ho A, de Stanchina E, Schwartz G . Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death. Mol Cancer Ther. 2013; 12(5):768-76. DOI: 10.1158/1535-7163.MCT-12-1020. View

Field M, Decatur C, Kurtenbach S, Gezgin G, van der Velden P, Jager M . PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma. Clin Cancer Res. 2016; 22(5):1234-42. PMC: 4780366. DOI: 10.1158/1078-0432.CCR-15-2071. View

Shields C, Ganguly A, Materin M, Teixeira L, Mashayekhi A, Swanson L . Chromosome 3 analysis of uveal melanoma using fine-needle aspiration biopsy at the time of plaque radiotherapy in 140 consecutive cases: the Deborah Iverson, MD, Lectureship. Arch Ophthalmol. 2007; 125(8):1017-24. DOI: 10.1001/archopht.125.8.1017. View

Blanco P, Lim L, Miyamoto C, Burnier M . Uveal melanoma dormancy: an acceptable clinical endpoint?. Melanoma Res. 2012; 22(5):334-40. DOI: 10.1097/CMR.0b013e328357bea8. View

van der Kooij M, Speetjens F, van der Burg S, Kapiteijn E . Uveal Versus Cutaneous Melanoma; Same Origin, Very Distinct Tumor Types. Cancers (Basel). 2019; 11(6). PMC: 6627906. DOI: 10.3390/cancers11060845. View

Carbone M, Ferris L, Baumann F, Napolitano A, Lum C, Flores E . BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med. 2012; 10:179. PMC: 3493315. DOI: 10.1186/1479-5876-10-179. View

McLaughlin C, Wu X, Jemal A, Martin H, Roche L, Chen V . Incidence of noncutaneous melanomas in the U.S. Cancer. 2005; 103(5):1000-7. DOI: 10.1002/cncr.20866. View

Shah S, Luke J, Jacene H, Chen T, Giobbie-Hurder A, Ibrahim N . Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma. Melanoma Res. 2018; 28(6):605-610. DOI: 10.1097/CMR.0000000000000509. View

10.

Mahendraraj K, Lau C, Lee I, Chamberlain R . Trends in incidence, survival, and management of uveal melanoma: a population-based study of 7,516 patients from the Surveillance, Epidemiology, and End Results database (1973-2012). Clin Ophthalmol. 2016; 10:2113-2119. PMC: 5087706. DOI: 10.2147/OPTH.S113623. View

11.

Damato B, Duke C, Coupland S, Hiscott P, Smith P, Campbell I . Cytogenetics of uveal melanoma: a 7-year clinical experience. Ophthalmology. 2007; 114(10):1925-31. DOI: 10.1016/j.ophtha.2007.06.012. View

12.

Worley L, Onken M, Person E, Robirds D, Branson J, Char D . Transcriptomic versus chromosomal prognostic markers and clinical outcome in uveal melanoma. Clin Cancer Res. 2007; 13(5):1466-71. DOI: 10.1158/1078-0432.CCR-06-2401. View

13.

Arulananda S, Parakh S, Palmer J, Goodwin M, Andrews M, Cebon J . A pilot study of intrahepatic yttrium-90 microsphere radioembolization in combination with intravenous cisplatin for uveal melanoma liver-only metastases. Cancer Rep (Hoboken). 2020; 2(4):e1183. PMC: 7941455. DOI: 10.1002/cnr2.1183. View

14.

Seth R, Messersmith H, Kaur V, Kirkwood J, Kudchadkar R, McQuade J . Systemic Therapy for Melanoma: ASCO Guideline. J Clin Oncol. 2020; 38(33):3947-3970. DOI: 10.1200/JCO.20.00198. View

15.

Bishop K, Olszewski A . Epidemiology and survival outcomes of ocular and mucosal melanomas: a population-based analysis. Int J Cancer. 2013; 134(12):2961-71. DOI: 10.1002/ijc.28625. View

16.

Virgili G, Gatta G, Ciccolallo L, Capocaccia R, Biggeri A, Crocetti E . Incidence of uveal melanoma in Europe. Ophthalmology. 2007; 114(12):2309-15. DOI: 10.1016/j.ophtha.2007.01.032. View

17.

Hawkins B . The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24. Am J Ophthalmol. 2005; 138(6):936-51. DOI: 10.1016/j.ajo.2004.07.006. View

18.

Huang Y, Yuan J, Righi E, Kamoun W, Ancukiewicz M, Nezivar J . Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A. 2012; 109(43):17561-6. PMC: 3491458. DOI: 10.1073/pnas.1215397109. View

19.

Ly L, Baghat A, Versluis M, Jordanova E, Luyten G, van Rooijen N . In aged mice, outgrowth of intraocular melanoma depends on proangiogenic M2-type macrophages. J Immunol. 2010; 185(6):3481-8. DOI: 10.4049/jimmunol.0903479. View

20.

Haas N, Quirt I, Hotte S, McWhirter E, Polintan R, Litwin S . Phase II trial of vorinostat in advanced melanoma. Invest New Drugs. 2014; 32(3):526-34. DOI: 10.1007/s10637-014-0066-9. View